Exelixis (EXEL)

Exelixis (EXEL) Stock Price & Analysis


EXEL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$14.87 - $22.80
Previous Close$21.75
Average Volume (3M)2.19M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$194.69M
Price to Earnings (P/E)43.3
Oct 31, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding318,380,785
10 Day Avg. Volume2,439,077
30 Day Avg. Volume2,191,780
Standard Deviation0.13
Financial Highlights & Ratios
Price to Book (P/B)2.82
Price to Sales (P/S)14.74
Price to Cash Flow (P/CF)20.80
P/FCF Ratio22.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside18.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15



Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $14.87 and its highest was $22.80 in the past 12 months.
    What is Exelixis’s market cap?
    Currently, no data Available
    When is Exelixis’s upcoming earnings report date?
    Exelixis’s upcoming earnings report date is Oct 31, 2023 which is in 34 days.
      How were Exelixis’s earnings last quarter?
      Exelixis released its earnings results on Aug 01, 2023. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.165 by $0.085.
        Is Exelixis overvalued?
        According to Wall Street analysts Exelixis’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Exelixis pay dividends?
          Exelixis does not currently pay dividends.
          What is Exelixis’s EPS estimate?
          Exelixis’s EPS estimate is $0.2.
            How many shares outstanding does Exelixis have?
            Exelixis has 318,380,800 shares outstanding.
              What happened to Exelixis’s price movement after its last earnings report?
              Exelixis reported an EPS of $0.25 in its last earnings report, beating expectations of $0.165. Following the earnings report the stock price went up 3.617%.
                Which hedge fund is a major shareholder of Exelixis?
                Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 494M.


                  Exelixis Stock Smart Score

                  The Exelixis stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.


                  Top 5 ETFs holding EXEL

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Russell 1000 Growth ETF
                  Vanguard Russell 1000 ETF
                  Vanguard Russell 3000 ETF
                  Invesco S&P US Total Market ESG Tilt Index ETF Trust Units -CAD Hedged-
                  Up to five ETFs with an Outperform Smart Score that hold EXEL. The ETFs are listed according to market value of EXEL within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Arrowhead Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis